Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.

MLA

Ray-Coquard, Isabelle, et al. “Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-Ov7 Randomized Clinical Trial.” JAMA Oncology, vol. 6, no. 12, Dec. 2020, pp. 1923–30. EBSCOhost, https://doi.org/10.1001/jamaoncol.2020.4574.

APA

Ray-Coquard, I., Harter, P., Lorusso, D., Dalban, C., Vergote, I., Fujiwara, K., Gladieff, L., Lück, H.-J., Floquet, A., Chevalier-Place, A., Schnelzer, A., Pignata, S., Selle, F., Sehouli, J., Brocard, F., Mangili, G., Pautier, P., De Giorgi, U., Provansal, M., & Heudel, P.-E. (2020). Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial. JAMA Oncology, 6(12), 1923–1930. https://doi.org/10.1001/jamaoncol.2020.4574

Chicago

Ray-Coquard, Isabelle, Philipp Harter, Domenica Lorusso, Cécile Dalban, Ignace Vergote, Keiichi Fujiwara, Laurence Gladieff, et al. 2020. “Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-Ov7 Randomized Clinical Trial.” JAMA Oncology 6 (12): 1923–30. doi:10.1001/jamaoncol.2020.4574.